People living with early Alzheimer's disease often face a difficult choice. They hope for treatments that can slow the decline of memory and thinking skills. This new research offers a clear answer for those hoping oral semaglutide could help. The study looked at people with confirmed Alzheimer's who had mild cognitive impairment or mild dementia. These are the stages where symptoms are noticeable but not yet severe. Many patients and families have been waiting for effective new options. This trial tested whether a daily pill could change the course of the illness.
The researchers ran a very large test involving 3808 people. These participants were spread across 566 medical sites in 40 different countries. This wide reach makes the results very reliable. The study was split into two parts called EVOKE and EVOKE+. Participants took either oral semaglutide or a placebo pill that looked the same but had no active medicine. The goal was to see if the drug could stop the disease from getting worse over time.
The main measure of success was how dementia scores changed over the study period. Doctors track these scores to see if thinking skills are declining faster or slower. At the end of the main follow-up period, the results showed no difference between the two groups. In the first part of the study, the average score change was 2.3 for the drug group and 2.3 for the placebo group. In the second part, the scores were 2.2 for the drug group and 2.1 for the placebo group. These tiny differences were not statistically significant. This means the drug did not work better than the sugar pill.
Safety was also a major part of the study. Side effects were common in both groups. About 91 percent of people taking the drug had some side effect compared to 85 percent of those on the placebo. There were five deaths during the study. Investigators thought one death might be related to the drug and four might be related to the placebo. The safety profile matched what is seen with this drug in other health conditions. However, the lack of benefit means the risks of side effects are not worth it for this specific disease.
It is important not to overreact to this news. This was a Phase 3 trial, which is one of the final steps before a drug is approved for a specific use. The results are clear and come from a massive number of participants. While this drug helps with weight loss and diabetes, it does not help with Alzheimer's disease. Patients should not stop or start this medication based on this study alone without talking to their doctor. The study confirms that this specific treatment is not the answer for early Alzheimer's.
For patients right now, this study means there is no new oral pill option for this condition. Families should focus on other proven strategies to manage symptoms and maintain quality of life. This research closes a door on a popular hope but opens the path to finding other solutions. Science moves forward by testing ideas that do not work so we can focus on what does. This trial helps doctors give honest advice to patients who are looking for hope.